ACADIA Pharmaceuticals (ACAD) reopens for trade, soaring 144% following the success of its Phase...

|About: ACADIA Pharmaceuticals Inc. (ACAD)|By:, SA News Editor

ACADIA Pharmaceuticals (ACAD) reopens for trade, soaring 144% following the success of its Phase III trial for Pimavanserin. "Home run for them," is Jason Napodano's quick take after looking over the data. Of particular interest, he says, is the testing showed no negative impact on motor function, unlike clozapine or quetiapine.